Lemborexant’s marketing status and drug registration information

Lemborexant was first approved by the FDA in the United States in 2019 and is marketed under the trade name Dayvigo. It is used to treat adult insomnia, especially patients with difficulty falling asleep and maintaining sleep. As a non-benzodiazepine orexin receptor antagonist, the approval of leborexan marks a new stage of precision in the treatment of insomnia. Compared with traditional drugs, it has obvious advantages in safety, dependence and tolerance control. Before its launch, Lebrasant has demonstrated its effectiveness and safety in multi-center registered clinical trials around the world, covering different age groups and types of insomnia, laying a scientific basis for its official launch.

In China, the original drug of Lebraxen has been approved for marketing by the drug administration department under the trade name of Daweike. During the registration process, drugs have completed comprehensive pharmaceutical research and clinical verification to ensure their safety, stability and effectiveness. After its launch, domestic hospitals and pharmacies can provide the drug to eligible insomnia patients based on prescription. This approval not only provides new treatment options for clinical use, but also provides patients with a long-term, stable and controllable sleep management solution. In the Chinese market, doctors can use Lebrasin as a first-line or second-line treatment based on the patient's specific insomnia type and medical history, supplemented by sleep hygiene and lifestyle intervention to maximize the treatment effect.

Additionally, the launch marks more flexibility for clinicians in selecting treatment options. The approval of Lebraxen is based on extensive clinical data and safety monitoring, providing a scientific basis for future use in different populations and different types of insomnia. By continuously observing the safety, tolerability and long-term efficacy of drugs, patients can achieve more precise and personalized sleep treatment under the guidance of doctors.

Reference materials:https://medlineplus.gov/druginfo/meds/a620039.html